Theravance Biopharma (TBPH) Competitors $10.04 -0.04 (-0.40%) (As of 12/11/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TBPH vs. IRON, HRMY, MNKD, GLPG, XNCR, ARVN, DVAX, NAMS, EVO, and RCUSShould you be buying Theravance Biopharma stock or one of its competitors? The main competitors of Theravance Biopharma include Disc Medicine (IRON), Harmony Biosciences (HRMY), MannKind (MNKD), Galapagos (GLPG), Xencor (XNCR), Arvinas (ARVN), Dynavax Technologies (DVAX), NewAmsterdam Pharma (NAMS), Evotec (EVO), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical preparations" industry. Theravance Biopharma vs. Disc Medicine Harmony Biosciences MannKind Galapagos Xencor Arvinas Dynavax Technologies NewAmsterdam Pharma Evotec Arcus Biosciences Theravance Biopharma (NASDAQ:TBPH) and Disc Medicine (NASDAQ:IRON) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, community ranking, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation. Does the media favor TBPH or IRON? In the previous week, Disc Medicine had 11 more articles in the media than Theravance Biopharma. MarketBeat recorded 19 mentions for Disc Medicine and 8 mentions for Theravance Biopharma. Disc Medicine's average media sentiment score of 0.70 beat Theravance Biopharma's score of 0.21 indicating that Disc Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Theravance Biopharma 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Disc Medicine 6 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is TBPH or IRON more profitable? Disc Medicine has a net margin of 0.00% compared to Theravance Biopharma's net margin of -78.18%. Theravance Biopharma's return on equity of -24.79% beat Disc Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Theravance Biopharma-78.18% -24.79% -13.43% Disc Medicine N/A -25.24%-23.96% Which has more volatility & risk, TBPH or IRON? Theravance Biopharma has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Comparatively, Disc Medicine has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Do analysts rate TBPH or IRON? Theravance Biopharma presently has a consensus price target of $13.75, indicating a potential upside of 36.95%. Disc Medicine has a consensus price target of $87.50, indicating a potential upside of 32.72%. Given Theravance Biopharma's higher probable upside, analysts plainly believe Theravance Biopharma is more favorable than Disc Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Theravance Biopharma 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Disc Medicine 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10 Does the MarketBeat Community believe in TBPH or IRON? Theravance Biopharma received 292 more outperform votes than Disc Medicine when rated by MarketBeat users. However, 84.48% of users gave Disc Medicine an outperform vote while only 62.80% of users gave Theravance Biopharma an outperform vote. CompanyUnderperformOutperformTheravance BiopharmaOutperform Votes34162.80% Underperform Votes20237.20% Disc MedicineOutperform Votes4984.48% Underperform Votes915.52% Do institutionals and insiders believe in TBPH or IRON? 99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 6.9% of Theravance Biopharma shares are held by company insiders. Comparatively, 4.2% of Disc Medicine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has preferable valuation and earnings, TBPH or IRON? Theravance Biopharma has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTheravance Biopharma$57.42M8.60-$55.19M-$1.01-9.94Disc MedicineN/AN/A-$76.43M-$3.98-16.57 SummaryTheravance Biopharma beats Disc Medicine on 10 of the 18 factors compared between the two stocks. Ad The Cashflow AcademyWant to Start Investing? It’s Easier Than You Think!Many people think you need a lot of money to start investing—but that’s simply not true. Andy Tanner, Rich Dad Expert, has spent 25+ years teaching everyday people how to build wealth—even with small amounts of money.👉 Click here to reserve your free spot! Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TBPH vs. The Competition Export to ExcelMetricTheravance BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$493.67M$6.89B$5.25B$9.28BDividend YieldN/A3.01%5.12%3.95%P/E Ratio-9.9410.61135.8517.65Price / Sales8.60229.381,253.19141.07Price / CashN/A22.6935.5735.65Price / Book2.355.404.824.95Net Income-$55.19M$152.46M$119.12M$225.72M7 Day Performance2.03%1.41%1.49%1.51%1 Month Performance12.68%-4.62%-0.57%4.96%1 Year Performance-7.38%24.00%33.08%29.01% Theravance Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TBPHTheravance Biopharma2.386 of 5 stars$10.04-0.4%$13.75+37.0%-6.9%$493.67M$57.42M-9.94359IRONDisc Medicine3.4571 of 5 stars$64.82+4.0%$85.80+32.4%+8.0%$1.93BN/A-16.2978Analyst ForecastNews CoverageHRMYHarmony Biosciences4.7761 of 5 stars$33.67-0.3%$47.00+39.6%+4.2%$1.92B$582.02M16.00200Short Interest ↓MNKDMannKind3.6888 of 5 stars$6.72-1.2%$8.67+29.0%+86.7%$1.85B$198.96M97.14400News CoverageGLPGGalapagos0.8042 of 5 stars$27.14+0.6%$30.75+13.3%-30.7%$1.79B$259.40M0.001,123Short Interest ↑Analyst RevisionNews CoverageXNCRXencor4.3056 of 5 stars$25.47+0.5%$36.50+43.3%+28.7%$1.78B$168.34M0.00280Positive NewsARVNArvinas2.3586 of 5 stars$25.28-2.5%$63.00+149.2%-33.3%$1.74B$78.50M0.00445Analyst ForecastShort Interest ↑DVAXDynavax Technologies4.8218 of 5 stars$12.90+0.4%$22.00+70.5%-3.7%$1.70B$232.28M98.85408Short Interest ↓Positive NewsNAMSNewAmsterdam Pharma2.5874 of 5 stars$18.19-0.9%$33.80+85.8%+158.5%$1.68B$14.09M0.0057Analyst ForecastShort Interest ↑News CoverageGap UpEVOEvotec2.3439 of 5 stars$4.69+1.7%$5.93+26.5%-52.5%$1.66B$845.74M0.005,061Short Interest ↓News CoverageRCUSArcus Biosciences2.6102 of 5 stars$17.83+3.1%$34.00+90.7%+12.3%$1.63B$263M-5.59500 Related Companies and Tools Related Companies IRON Alternatives HRMY Alternatives MNKD Alternatives GLPG Alternatives XNCR Alternatives ARVN Alternatives DVAX Alternatives NAMS Alternatives EVO Alternatives RCUS Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TBPH) was last updated on 12/12/2024 by MarketBeat.com Staff From Our PartnersEx-Lawyer turns $50k into $5 million tradingHe was a lawyer by day, secret trader by night...or in this case by lunch… With nothing but a laptop and a ...Investing Daily | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredWant to Start Investing? It’s Easier Than You Think!Many people think you need a lot of money to start investing—but that’s simply not true. Andy Tanner, Rich ...The Cashflow Academy | SponsoredPrepare Now Before This Looming $2 Trillion D.C. ShockMillions of traders could get blindsided by this election-year shock on December 18th… And if you do nothin...Timothy Sykes | SponsoredVance Exposes Wall Street Plan to Crash Bonds, Target TrumpJ.D. Vance just dropped a bombshell: With Trump in office, Wall Street could drive the bond market into a deat...Golden Crest | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theravance Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TBPH Stock Alerts